FORMA Therapeutics Announces Collaboration Wtih Novartis AG to Discover Inhibitors of Protein-Protein Interactions for Oncology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FORMA Therapeutics announced today that it has entered into a collaboration agreement with Novartis. Under the terms of the agreement, FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets in the field of oncology. Financial terms of the collaboration were not disclosed.

Back to news